Industry
Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
ED action in Reliance Anil Ambani Group cases | Explained
CERT-In calls for testing AI agents for unauthorised tool use, privilege abuse
India secures $400-bn investment commitments in renewables; ALMM review in 15 days
Apollo Hospitals’ Q2 revenue rises 23%; profit up 32% on broad-based growth
Alembic Pharma Q2 net surges 81% to ₹335 crore
The Hindu - Industry·5 Nov 2026
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
More news in Industry
Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenueED action in Reliance Anil Ambani Group cases | ExplainedCERT-In calls for testing AI agents for unauthorised tool use, privilege abuseIndia secures $400-bn investment commitments in renewables; ALMM review in 15 daysApollo Hospitals’ Q2 revenue rises 23%; profit up 32% on broad-based growth